AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6703348 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine 7.5 mg
Number of subjects: 40
Study 6703348 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 40
Study 6703348 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine (all doses)
Number of subjects: 40
Study 30624568 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of phylloquinone (vitamin K-1)
Number of subjects: 28356
Study 30624568 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of menaquinones (vitamin K-2)
Number of subjects: 28356
Study 30624568 — intervention group
Group type: EXPERIMENTAL
Intervention: Total dietary intake of vitamin K
Number of subjects: 28356
Study 29939764 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support (CDS) in high-complexity conditions
Number of subjects: 120
Study 29939764 — intervention group
Group type: COMPARATOR
Intervention: No Clinical Decision Support (no CDS) in high-complexity conditions
Number of subjects: 120
Study 29939764 — intervention group
Group type: EXPERIMENTAL
Intervention: Low task complexity
Number of subjects: 120
Study 24503279 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate as add-on therapy to mirtazapine
Number of subjects: 88
Study 24503279 — intervention group
Group type: COMPARATOR
Intervention: Placebo as add-on therapy to mirtazapine
Number of subjects: 88
Study 21920461 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 0
Study 21920461 — intervention group
Group type: COMPARATOR
Intervention: Psychotherapy control
Number of subjects: 0
Study 19188136 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab (400 mg/m² day 1 followed by weekly 250 mg/m²) + paclitaxel (225 mg/m²)/carboplatin (AUC6) day 1 every 3 weeks
Number of subjects: 168
Study 19188136 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab (400 mg/m² day 1 followed by weekly 250 mg/m²) + paclitaxel (100 mg/m²) days 1, 8, and 15 every 3 weeks and carboplatin (AUC6) day 1 every 4 weeks
Number of subjects: 168
Study 17205514 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampling for hrHPV testing
Number of subjects: 284
Study 17205514 — intervention group
Group type: COMPARATOR
Intervention: Control group (extra recall for conventional cytology)
Number of subjects: 284
Study 15970000 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal FSH suppression by physiological oestradiol doses
Number of subjects: 0
Study 15970000 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal oestradiol administration
Number of subjects: 0
Study 15970000 — intervention group
Group type: EXPERIMENTAL
Intervention: Premenstrual GnRH antagonist administration
Number of subjects: 0
Study 12532716 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant radio-chemotherapy
Number of subjects: 0
Study 12532716 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory and experimental investigations
Number of subjects: 0
Study 9881328 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg of conjugated equine estrogen (CEE) daily (group 1)
Number of subjects: 63
Study 9881328 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg of conjugated equine estrogen (CEE) daily (group 2)
Number of subjects: 63
Study 9881328 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 63
Study 7997385 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsemide 10 mg
Number of subjects: 66
Study 7997385 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsemide 20 mg
Number of subjects: 66
Study 7997385 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsemide 5 mg
Number of subjects: 66
Study 7997385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 3396459 — intervention group
Group type: EXPERIMENTAL
Intervention: Auxiliary prescription labels (study sticker)
Number of subjects: 559
Study 3396459 — intervention group
Group type: COMPARATOR
Intervention: No auxiliary prescription labels (control group)
Number of subjects: 559
Study 31758556 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU + 7 weekly 90-minute sessions of AF-EMDR (N = 55)
Number of subjects: 109
Study 31758556 — intervention group
Group type: COMPARATOR
Intervention: TAU-only (N = 54)
Number of subjects: 109
Study 29567761 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous IL-1 receptor antagonist (IL-1Ra) 100 mg administered twice daily for 3 days
Number of subjects: 80
Study 29567761 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 80
Study 29293697 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D 200 IU/d
Number of subjects: 0
Study 29293697 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D 400 IU/d
Number of subjects: 0
Study 29293697 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D 600 IU/d
Number of subjects: 0
Study 29293697 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D 800 IU/d
Number of subjects: 0
Study 29293697 — intervention group
Group type: COMPARATOR
Intervention: Control (no vitamin D supplementation)
Number of subjects: 0
Study 26198744 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 70)
Number of subjects: 140
Study 26198744 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 70)
Number of subjects: 140
Study 23927819 — intervention group
Group type: EXPERIMENTAL
Intervention: High‐intensity aerobic interval exercise (HIA)
Number of subjects: 115
Study 23927819 — intervention group
Group type: COMPARATOR
Intervention: Home‐based exercise (HB)
Number of subjects: 115
Study 21923854 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified constraint‐induced therapy (mitt on the unaffected hand for 2 hours each day for 8 weeks)
Number of subjects: 50
Study 21923854 — intervention group
Group type: COMPARATOR
Intervention: Intensive occupational therapy (8 weeks)
Number of subjects: 50
Study 19144261 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine HCl nasal spray 0.6% (OLO)
Number of subjects: 110
Study 16697452 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component intervention including classroom-based curricula, family newsletters, and changes in the school food environment.
Number of subjects: 3600
Study 16697452 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention schools
Number of subjects: 3600
Study 16697452 — intervention group
Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 3600
Study 12846417 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemical (IHC) ODC assay
Number of subjects: 433
Study 10976548 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (21 mg patch)
Number of subjects: 21
Study 10976548 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside
Number of subjects: 21
Study 9002806 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered lidocaine
Number of subjects: 20
Study 9002806 — intervention group
Group type: COMPARATOR
Intervention: Conventional 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 20
Study 1404796 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium chloride, 2 g intravenous infusion
Number of subjects: 100
Study 1404796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 1404796 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative normomagnesemic patients
Number of subjects: 100
Study 1404796 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative hypomagnesemic patients
Number of subjects: 100
Study 4003371 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin antibiotic prophylaxis
Number of subjects: 33
Study 4003371 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 31062728 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene Blue (MB)
Number of subjects: 237
Study 31062728 — intervention group
Group type: COMPARATOR
Intervention: Patent Blue Violet (PBV)
Number of subjects: 237
Study 29598955 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain during chemotherapy (≥ 5% increase)
Number of subjects: 1080
Study 29598955 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss during chemotherapy (≥ 5% decrease)
Number of subjects: 1080
Study 29598955 — intervention group
Group type: COMPARATOR
Intervention: Stable weight during chemotherapy
Number of subjects: 1080
Study 26913399 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOPE regimen combined with thalidomide
Number of subjects: 80
Study 26913399 — intervention group
Group type: COMPARATOR
Intervention: CHOPE regimen alone
Number of subjects: 80
Study 24667057 — intervention group
Group type: EXPERIMENTAL
Intervention: Otologic Compass (OC)
Number of subjects: 25
Study 24667057 — intervention group
Group type: COMPARATOR
Intervention: Fisch elevator (Control)
Number of subjects: 25
Study 22104168 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic intervention focused on relieving muscle hypertonicity in the deep compartment of the lower leg and restoring balance of the toe flexors and extensors (n = 7)
Number of subjects: 20
Study 22104168 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control group, n = 6)
Number of subjects: 20
Study 20551303 — intervention group
Group type: EXPERIMENTAL
Intervention: SNPs (rs12334903, rs1456310, rs980171)
Number of subjects: 563
Study 20551303 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster of nine SNPs in prostate cancer risk region 1
Number of subjects: 563
Study 18630535 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple cupping at back-shu points (n = 142)
Number of subjects: 191
Study 18630535 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture at acupoints (n = 49)
Number of subjects: 191
Study 15921758 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.59‐mg fluocinolone acetonide intravitreal implant
Number of subjects: 32
Study 15921758 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.1‐mg fluocinolone acetonide intravitreal implant
Number of subjects: 32
Study 15921758 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 32
Study 12358873 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous combined hormone replacement therapy (n = 29) with conjugated equine oestrogen (0.625 mg/day) plus medroxyprogesterone acetate (2.5 mg/day)
Number of subjects: 61
Study 12358873 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 32)
Number of subjects: 61
Study 10415739 — intervention group
Group type: EXPERIMENTAL
Intervention: Subantimicrobial dose of doxycycline (SDD)
Number of subjects: 0
Study 10415739 — intervention group
Group type: COMPARATOR
Intervention: Control groups (placebo)
Number of subjects: 0
Study 7489696 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin (PHT)
Number of subjects: 31
Study 7489696 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine (CBZ)
Number of subjects: 31
Study 2105538 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 100 mg daily for 2 months
Number of subjects: 16
Study 2105538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 473929 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular administration of 125 mg/0.5 ml Arteparon (6 injections)
Number of subjects: 100
Study 473929 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of 125 mg/0.5 ml Arteparon (10 injections)
Number of subjects: 100
Study 473929 — intervention group
Group type: COMPARATOR
Intervention: Intraarticular and Intramuscular administration of Arteparon
Number of subjects: 100
Study 31429381 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional IPC (15-min preceding the trial)
Number of subjects: 12
Study 31429381 — intervention group
Group type: EXPERIMENTAL
Intervention: IPC x 2 (24-h and 15-min preceding)
Number of subjects: 12
Study 31429381 — intervention group
Group type: EXPERIMENTAL
Intervention: IPC x 3 (48-h, 24-h, and 15-min preceding)
Number of subjects: 12
Study 31429381 — intervention group
Group type: COMPARATOR
Intervention: Control average (CONavg)
Number of subjects: 12
Study 31465446 — intervention group
Group type: EXPERIMENTAL
Intervention: Public observation
Number of subjects: 120
Study 31465446 — intervention group
Group type: EXPERIMENTAL
Intervention: Private observation
Number of subjects: 120
Study 31465446 — intervention group
Group type: COMPARATOR
Intervention: Non-social control
Number of subjects: 120
Study 28031173 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous rituximab (1400 mg)
Number of subjects: 743
Study 28031173 — intervention group
Group type: COMPARATOR
Intervention: Intravenous rituximab (375 mg/m2)
Number of subjects: 743
Study 25037651 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheelchair‐bound Senior Elastic Band exercise program (40 minutes, three times per week for six months)
Number of subjects: 114
Study 25037651 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 114
Study 23419328 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS (n = 22)
Number of subjects: 42
Study 23419328 — intervention group
Group type: COMPARATOR
Intervention: Placebo-TENS (n = 20)
Number of subjects: 42
Study 21042188 — intervention group
Group type: EXPERIMENTAL
Intervention: Furlow double‐opposing Z‐palatoplasty
Number of subjects: 0
Study 21042188 — intervention group
Group type: COMPARATOR
Intervention: von Langenbeck procedure
Number of subjects: 0
Study 19512978 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 15 mg/d
Number of subjects: 0
Study 19512978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16889680 — intervention group
Group type: EXPERIMENTAL
Intervention: OPCAB (off-pump coronary artery bypass grafting)
Number of subjects: 60
Study 16889680 — intervention group
Group type: COMPARATOR
Intervention: CABG (on-pump coronary artery bypass grafting)
Number of subjects: 60
Study 16889680 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 60
Study 15264976 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help materials plus video
Number of subjects: 402
Study 15264976 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help materials, video, and telephone counseling
Number of subjects: 402
Study 11527567 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline iontophoresis at a current density of 0.2 mA/cm(2) for 4 hours
Number of subjects: 30
Study 9269212 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 530
Study 9269212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 530
Study 8511923 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) with PMUE therapy: cisplatin (CDDP) 75 mg/m2, mitomycin C (MMC) 10 mg/body, etoposide 150 mg/body, and UFT 400 mg/day.
Number of subjects: 55
Study 8511923 — intervention group
Group type: COMPARATOR
Intervention: Control group (surgery first, then PMUE therapy).
Number of subjects: 55
Study 8511923 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC) group.
Number of subjects: 55
Study 8511923 — intervention group
Group type: COMPARATOR
Intervention: Control group.
Number of subjects: 55
Study 8511923 — intervention group
Group type: EXPERIMENTAL
Intervention: Resection cases in NAC group.
Number of subjects: 55
Study 3325230 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycosaminoglycan-peptide complex ('Rumalon')
Number of subjects: 50
Study 3325230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 30402206 — intervention group
Group type: EXPERIMENTAL
Intervention: High vegetable consumption (4200 g of vegetables/week)
Number of subjects: 38
Study 30402206 — intervention group
Group type: COMPARATOR
Intervention: Low vegetable consumption (800 g of vegetables/week)
Number of subjects: 38
Study 27026012 — intervention group
Group type: EXPERIMENTAL
Intervention: IoC1 and IoC2 monitoring
Number of subjects: 120
Study 27026012 — intervention group
Group type: COMPARATOR
Intervention: Control group (C group)
Number of subjects: 120
Study 24819044 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus meeting
Number of subjects: 0
Study 24819044 — intervention group
Group type: COMPARATOR
Intervention: Adjustment of the regulatory instrument
Number of subjects: 0
Study 24819044 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing the number of inspectors per regulatory visit
Number of subjects: 0
Study 22875224 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced Wound Care (AWC) dressings
Number of subjects: 62
Study 22875224 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum‐assisted closure (VAC) therapy
Number of subjects: 62
Study 21081024 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational conjunctival flap (RCF) surgery
Number of subjects: 0
Study 21081024 — intervention group
Group type: COMPARATOR
Intervention: Simple conjunctival closure (SCC)
Number of subjects: 0
Study 18682346 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive small-group social norms correction
Number of subjects: 502
Study 18682346 — intervention group
Group type: COMPARATOR
Intervention: Noninteractive social norms education
Number of subjects: 502
Study 15883427 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dietary zinc intake (3.8 mg/d)
Number of subjects: 14
Study 15883427 — intervention group
Group type: COMPARATOR
Intervention: Supplemented zinc intake (18.7 mg/d)
Number of subjects: 14
Study 12452732 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal formulation of anthracyclines
Number of subjects: 0
Study 12452732 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline-derivatives with lower toxicity
Number of subjects: 0
Study 12452732 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioprotective agents
Number of subjects: 0
Study 12452732 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of anthracyclines
Number of subjects: 0
Study 12452732 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed sequential therapy
Number of subjects: 0
Study 12452732 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexrazoxane
Number of subjects: 0
Study 12452732 — intervention group
Group type: EXPERIMENTAL
Intervention: New diagnostic methods for minimal residual disease
Number of subjects: 0
Study 10511019 — intervention group
Group type: EXPERIMENTAL
Intervention: Small capsulorhexis (4.5 to 5 mm)
Number of subjects: 75
Study 10511019 — intervention group
Group type: COMPARATOR
Intervention: Large capsulorhexis (6 to 7 mm)
Number of subjects: 75
Study 7740949 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cefadroxil
Number of subjects: 52
Study 7740949 — intervention group
Group type: COMPARATOR
Intervention: Parenteral cefuroxime
Number of subjects: 52
Study 1889702 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 106
Study 1889702 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 106
Study 1889702 — intervention group
Group type: EXPERIMENTAL
Intervention: Sclerotherapy (among those who bled)
Number of subjects: 106
Study 1889702 — intervention group
Group type: COMPARATOR
Intervention: Control (among those who bled)
Number of subjects: 106
Study 7069203 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA treatment
Number of subjects: 3
Study 7069203 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA treatment
Number of subjects: 3
Study 7069203 — intervention group
Group type: COMPARATOR
Intervention: 8‐methoxypsoralen treatment
Number of subjects: 3
Study 31151450 — intervention group
Group type: EXPERIMENTAL
Intervention: PBL plus high fidelity simulation training
Number of subjects: 112
Study 31151450 — intervention group
Group type: COMPARATOR
Intervention: Control group (90-min tutor-guided CPR hands-on training)
Number of subjects: 112
Study 27834589 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed-ice pack applied to the shoulder for 15 min
Number of subjects: 48
Study 27834589 — intervention group
Group type: COMPARATOR
Intervention: Control group applied a sandbag at skin temperature for 15 min
Number of subjects: 48
Study 25260059 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic fixation (TightRope; Arthrex)
Number of subjects: 70
Study 25260059 — intervention group
Group type: COMPARATOR
Intervention: Static fixation (3.5‐mm metallic screw)
Number of subjects: 70
Study 24332521 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue-violet LED irradiation after tooth extraction
Number of subjects: 0
Study 24332521 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue-violet LED irradiation combined with hemostatic gelatin sponge
Number of subjects: 0
Study 24332521 — intervention group
Group type: COMPARATOR
Intervention: Hemostatic gelatin sponge only
Number of subjects: 0
Study 22536131 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-gamma (IFN-γ) 50 μg/m² subcutaneously three times per week (n = 20)
Number of subjects: 40
Study 22536131 — intervention group
Group type: COMPARATOR
Intervention: Topical betamethasone valerate 0.1% cream every night for 30 days (n = 20)
Number of subjects: 40
Study 19696126 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Medical Research Council scale
Number of subjects: 101
Study 19696126 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered computerized versions of the baseline dyspnea index
Number of subjects: 101
Study 19696126 — intervention group
Group type: EXPERIMENTAL
Intervention: Transition dyspnea indexes
Number of subjects: 101
Study 19696126 — intervention group
Group type: EXPERIMENTAL
Intervention: University of San Diego Shortness of Breath Questionnaire
Number of subjects: 101
Study 19696126 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyspnea ratings
Number of subjects: 101
Study 17521397 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg b.i.d (12 patients)
Number of subjects: 22
Study 17521397 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets (10 patients)
Number of subjects: 22
Study 15203296 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine or Paroxetine (active medication)
Number of subjects: 0
Study 15203296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11380322 — intervention group
Group type: COMPARATOR
Intervention: LCM-7 (lansoprazole 30 mg, clarithromycin 500 mg, metronidazole 400 mg twice daily for 7 days)
Number of subjects: 118
Study 11380322 — intervention group
Group type: EXPERIMENTAL
Intervention: LCMB-3 (lansoprazole 30 mg, clarithromycin 500 mg, metronidazole 400 mg, bismuth subcitrate 240 mg twice daily for 3 days)
Number of subjects: 118